Industry economics)

Denise Vitola Joins Bayer Communications Team

Retrieved on: 
Monday, July 26, 2021

Bayer today announced Denise Vitola is joining the Bayer Communications Team as Vice President of Brand Integration, PR, Social and Influencer for Consumer Health.

Key Points: 
  • Bayer today announced Denise Vitola is joining the Bayer Communications Team as Vice President of Brand Integration, PR, Social and Influencer for Consumer Health.
  • Vitola will report to Beth Roden, SVP and Head of Communications Bayer U.S. and Head of Communications, Consumer Health North America.
  • Denise will also be a member of the U.S. Corporate Communications Leadership Team, driving reputation, digital excellence and integrated communications.
  • We are thrilled she is now officially a member of the Bayer Communications team and will continue to drive our successful integrated communications that has been an essential part of reaching our consumers and driving awareness of our brands.

Technip Energies: Availability of Half-Year Financial Report for the Period Ended 30 June 2021

Retrieved on: 
Monday, July 26, 2021

Technip Energies N.V. ("Technip Energies") (Paris:TE) (ISIN: NL0014559478) announces that on 26 July, 2021, it published its Half-Year Financial Report for the six months ended 30 June 2021.

Key Points: 
  • Technip Energies N.V. ("Technip Energies") (Paris:TE) (ISIN: NL0014559478) announces that on 26 July, 2021, it published its Half-Year Financial Report for the six months ended 30 June 2021.
  • The Half-Year Financial Report includes condensed consolidated financial statements (prepared in accordance with IAS 34), an interim management report and a statement of the persons responsible for the Half-Year Financial Report.
  • A copy of the Half-Year Financial Report can be found on Technip Energies website ( https://investors.technipenergies.com/financial-information/results-center ) and is, or will shortly be, available for inspection at https://www.info-financiere.fr .
  • In addition, Technip Energies has a Level 1 sponsored American Depositary Receipts (ADR) program, with its ADRs trading over-the-counter.

Arcus Biosciences Announces New Employment Inducement Grants

Retrieved on: 
Monday, July 26, 2021

The stock options were granted pursuant to the Companys 2020 Inducement Plan, which was approved by the Companys Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.

Key Points: 
  • The stock options were granted pursuant to the Companys 2020 Inducement Plan, which was approved by the Companys Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.
  • Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs.
  • An additional registrational Phase 3 study is being planned in collaboration with AstraZeneca in earlier disease with curative intent.
  • For more information about Arcus Biosciences, please visit www.arcusbio.com .

ParkOhio Announces Quarterly Dividend

Retrieved on: 
Monday, July 26, 2021

The Board of Directors of Park-Ohio Holdings Corp. (NASDAQ: PKOH) has declared a quarterly cash dividend of $0.125 per share on the common stock outstanding, to be paid on August 20, 2021, to shareholders of record as of the close of business on August 6, 2021.

Key Points: 
  • The Board of Directors of Park-Ohio Holdings Corp. (NASDAQ: PKOH) has declared a quarterly cash dividend of $0.125 per share on the common stock outstanding, to be paid on August 20, 2021, to shareholders of record as of the close of business on August 6, 2021.
  • ParkOhio is a diversified international company providing world-class customers with a supply chain management outsourcing service, capital equipment used on their production lines, and manufactured components used to assemble their products.
  • Headquartered in Cleveland, Ohio, ParkOhio operates more than 120 manufacturing sites and supply chain logistics facilities worldwide, through three reportable segments: Supply Technologies, Assembly Components and Engineered Products.
  • Risk Factors included in the Companys Annual Report on Form 10-K for the year ended December 31, 2020.

Tehama Appoints Nabeel Youakim as Chief Development Officer

Retrieved on: 
Monday, July 26, 2021

Tehama, provider of Enterprise-Ready Desktop as a Service, the fastest, easiest, most secure way to deploy a global workforce, today announced the appointment of Nabeel Youakim, as Chief Development Officer.

Key Points: 
  • Tehama, provider of Enterprise-Ready Desktop as a Service, the fastest, easiest, most secure way to deploy a global workforce, today announced the appointment of Nabeel Youakim, as Chief Development Officer.
  • We are thrilled to welcome Nabeel to the Tehama team, said Paul Valle, Founder and CEO of Tehama.
  • Prior to joining Tehama, Youakim provided business development and consulting services, advising businesses, technology providers and investment firms on technology trends, investment opportunities and go-to-market strategies.
  • TEHAMA and the Tehama logo are trademarks of Tehama Inc. or its affiliates.

Global Drug Delivery Devices Market Report 2021: Unit Volumes & Pricing Forecasts 2020-2025, Impact of COVID-19, Market Share Analysis, Leading Companies - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021

The "Global Drug Delivery Devices Market to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Drug Delivery Devices Market to 2025" report has been added to ResearchAndMarkets.com's offering.
  • This report covers the impact of COVID-19 on the drug delivery devices market, including a recent forecast from 2020 to 2025.
  • COVID-19 has also impacted leading competitors, such as BD, Baxter, Medtronic, Smiths Medical, and others.
  • The report provides insights into trends, drivers, and limiters of the drug delivery devices market, as well as highlights potential opportunities.

Metrion Biosciences appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development

Retrieved on: 
Monday, July 26, 2021

Metrion Biosciences Limited (Metrion), the specialist ion channel contract research and drug discovery company, today announced the appointment of Nick Foster as Chief Commercial Officer and Head of Global Business Development, to support the broadening of Metrions international customer base and facilitate entry into new territories.

Key Points: 
  • Metrion Biosciences Limited (Metrion), the specialist ion channel contract research and drug discovery company, today announced the appointment of Nick Foster as Chief Commercial Officer and Head of Global Business Development, to support the broadening of Metrions international customer base and facilitate entry into new territories.
  • Following his early career as a laboratory scientist, Nick moved into business development, holding positions as Associate Director, Business Development Europe for BioFocus Limited (now Charles River Laboratories), Head of Commercial Operations at Optibrium Limited, and Director, Business Development for WuXi AppTec.
  • Dr Andrew Southan, Chief Executive Officer of Metrion Biosciences, said: I am very pleased to welcome Nick to Metrions senior management team.
  • Nick Foster Chief Commercial Officer, Metrion BIosciences, commented: I am delighted to be joining Metrion at this exciting time of expansion for the company.

Romeo Power Announces Appointment of Matthew Sant as General Counsel

Retrieved on: 
Monday, July 26, 2021

Romeo Power, Inc. (Romeo Power) (NYSE: RMO), an energy technology leader delivering advanced electrification solutions for complex commercial vehicle applications, today announced the appointment of Matthew Sant to the role of General Counsel.

Key Points: 
  • Romeo Power, Inc. (Romeo Power) (NYSE: RMO), an energy technology leader delivering advanced electrification solutions for complex commercial vehicle applications, today announced the appointment of Matthew Sant to the role of General Counsel.
  • Mr. Sant is a seasoned in-house legal executive and lawyer who brings to Romeo Power extensive experience at the intersections of technology, business and legal issues.
  • Prior to joining Romeo Power, Mr. Sant served as Vice President and Deputy General Counsel at Skyworks Solutions, Inc. (NASDAQ: SWKS), a manufacturer of analog semiconductors for wireless communications.
  • Prior to this, Mr. Sant served as Vice President and Deputy General Counsel at Broadcom Corporation (NASDAQ: AVGO).

Intel Accelerates Process and Packaging Innovations

Retrieved on: 
Monday, July 26, 2021

At the event, Intel presented the company's future process and packaging technology roadmaps.

Key Points: 
  • At the event, Intel presented the company's future process and packaging technology roadmaps.
  • (Credit: Intel Corporation)
    Building on Intels unquestioned leadership in advanced packaging, we are accelerating our innovation roadmap to ensure we are on a clear path to process performance leadership by 2025, Intel CEO Pat Gelsinger said during the global Intel Accelerated webcast.
  • Intel 20A will be another watershed moment in process technology with two groundbreaking innovations: RibbonFET and PowerVia.
  • Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries.

Con Edison to Report 2nd Quarter 2021 Earnings on August 5

Retrieved on: 
Monday, July 26, 2021

NEW YORK, July 26, 2021 /PRNewswire/ -- Consolidated Edison, Inc. (Con Edison) (NYSE: ED) plans to report its 2nd Quarter 2021 earnings on August 5, 2021 after the market closes.

Key Points: 
  • NEW YORK, July 26, 2021 /PRNewswire/ -- Consolidated Edison, Inc. (Con Edison) (NYSE: ED) plans to report its 2nd Quarter 2021 earnings on August 5, 2021 after the market closes.
  • Consolidated Edison, Inc. is one of the nation's largest investor-owned energy-delivery companies, with approximately $12 billion in annual revenues and $62 billion in assets.
  • Con Edison Transmission manages, through joint ventures, both electric and gas assets while seeking to develop electric transmission projects that will bring clean, renewable electricity to customers, focusing on New York, New England, the Mid-Atlantic states and the Midwest.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/con-edison-to-report-2nd-quarte...